{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:03:04Z","timestamp":1790013784703,"version":"4.0.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02827-w","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T23:01:22Z","timestamp":1783638082000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Multifunctional-engineered NK cells overcome tumor immunosuppression by combining PD-L1 and HLA-E targeting and endogenous IL15 production"],"prefix":"10.1038","volume":"11","author":[{"given":"Piera Filomena","family":"Fiore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Forcelloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Moretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rita","family":"Assenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Orecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0293-7214","authenticated-orcid":false,"given":"Maria Teresa","family":"Bilotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Machwirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted","family":"Shpati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lokossou William","family":"Sanvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothee","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3920-7826","authenticated-orcid":false,"given":"Simone","family":"Vitozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Giansanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Nazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Tumino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9250-0605","authenticated-orcid":false,"given":"Ignazio","family":"Caruana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0757-0108","authenticated-orcid":false,"given":"Paola","family":"Vacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"2827_CR1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.21147\/j.issn.1000-9604.2023.03.03","volume":"35","author":"S Liu","year":"2023","unstructured":"Liu, S. & Zhang, Y. Challenges and interventions of chimeric antigen receptor-T cell therapy in solid tumors. Chin. J. Cancer Res. 35, 239\u2013244 (2023).","journal-title":"Chin. J. Cancer Res."},{"key":"2827_CR2","doi-asserted-by":"crossref","unstructured":"Johnson, A., Townsend, M. & O\u2019Neill, K. Tumor microenvironment immunosuppression: a roadblock to CAR T-cell advancement in solid tumors. Cells 11 (2022).","DOI":"10.3390\/cells11223626"},{"key":"2827_CR3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","volume":"25","author":"LA Kankeu Fonkoua","year":"2022","unstructured":"Kankeu Fonkoua, L. A., Sirpilla, O., Sakemura, R., Siegler, E. L. & Kenderian, S. S. C. A. R. T cell therapy and the tumor microenvironment: Current challenges and opportunities. Mol. Ther. Oncol. 25, 69\u201377 (2022).","journal-title":"Mol. Ther. Oncol."},{"key":"2827_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej, K. M. et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol. Cancer 22, 20 (2023).","journal-title":"Mol. Cancer"},{"key":"2827_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02305-x","volume":"24","author":"M Zhang","year":"2025","unstructured":"Zhang, M. et al. Advances in cancer immunotherapy: historical perspectives, current developments, and future directions. Mol. Cancer 24, 136 (2025).","journal-title":"Mol. Cancer"},{"key":"2827_CR6","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","volume":"10","author":"I Zugasti","year":"2025","unstructured":"Zugasti, I. et al. CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduct. Target Ther. 10, 210 (2025).","journal-title":"Signal Transduct. Target Ther."},{"key":"2827_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.18362","volume":"28","author":"Y Qi","year":"2024","unstructured":"Qi, Y. et al. Natural killer cell-related anti-tumour adoptive cell immunotherapy. J. Cell Mol. Med. 28, e18362 (2024).","journal-title":"J. Cell Mol. Med."},{"key":"2827_CR8","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","volume":"43","author":"B Du","year":"2025","unstructured":"Du, B. et al. CAR-T therapy in solid tumors. Cancer Cell 43, 665\u2013679 (2025).","journal-title":"Cancer Cell"},{"key":"2827_CR9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359\u2013371 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2827_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu, S. S. et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15, 47\u201362 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2827_CR11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13045-021-01193-0","volume":"14","author":"N Tumino","year":"2021","unstructured":"Tumino, N. et al. Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2.CAR T-cells in patients with neuroblastoma. J. Hematol. Oncol. 14, 191 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"2827_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02334-6","volume":"24","author":"Y Lu","year":"2025","unstructured":"Lu, Y. & Zhao, F. Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy. Mol. Cancer 24, 126 (2025).","journal-title":"Mol. Cancer"},{"key":"2827_CR13","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41392-022-01136-2","volume":"7","author":"DR Wang","year":"2022","unstructured":"Wang, D. R., Wu, X. L. & Sun, Y. L. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Signal Transduct. Target Ther. 7, 331 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"2827_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01899-4","volume":"22","author":"X Wu","year":"2023","unstructured":"Wu, X. et al. Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects. Mol. Cancer 22, 194 (2023).","journal-title":"Mol. Cancer"},{"key":"2827_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.09.010","volume":"6","author":"M Saetersmoen","year":"2025","unstructured":"Saetersmoen, M. et al. Targeting HLA-E-overexpressing cancers with a NKG2A\/C switch receptor. Med. 6, 100521 (2025).","journal-title":"Med"},{"key":"2827_CR16","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s10238-025-01641-y","volume":"25","author":"M Soltani","year":"2025","unstructured":"Soltani, M., Abbaszadeh, M., Fouladseresht, H., Sullman, M. J. M. & Eskandari, N. PD-L1 importance in malignancies comprehensive insights into the role of PD-L1 in malignancies: from molecular mechanisms to therapeutic opportunities. Clin. Exp. Med. 25, 106 (2025).","journal-title":"Clin. Exp. Med."},{"key":"2827_CR17","doi-asserted-by":"publisher","first-page":"1557030","DOI":"10.1080\/2162402X.2018.1557030","volume":"8","author":"FR Mariotti","year":"2019","unstructured":"Mariotti, F. R. et al. PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression. Oncoimmunology 8, 1557030 (2019).","journal-title":"Oncoimmunology"},{"key":"2827_CR18","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jaci.2016.04.025","volume":"139","author":"S Pesce","year":"2017","unstructured":"Pesce, S. et al. Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization. J. Allergy Clin. Immunol. 139, 335\u2013346 e333 (2017).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2827_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41421-024-00646-3","volume":"10","author":"X Liu","year":"2024","unstructured":"Liu, X. et al. Immune checkpoints HLA-E:CD94-NKG2A and HLA-C:KIR2DL1 complementarily shield circulating tumor cells from NK-mediated immune surveillance. Cell Discov. 10, 16 (2024).","journal-title":"Cell Discov."},{"key":"2827_CR20","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng, L., Sferruzza, G., Yang, L., Zhou, L. & Chen, S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol. Immunol. 21, 1089\u20131108 (2024).","journal-title":"Cell Mol. Immunol."},{"key":"2827_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/vaccines10121993","volume":"10","author":"JG Fisher","year":"2022","unstructured":"Fisher, J. G., Doyle, A. D. P., Graham, L. V., Khakoo, S. I. & Blunt, M. D. Disruption of the NKG2A:HLA-E immune checkpoint axis to enhance NK cell activation against cancer. Vaccines 10, 1\u201317 (2022).","journal-title":"Vaccines"},{"key":"2827_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2024-009934","volume":"12","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. Unlocking the therapeutic potential of the NKG2A-HLA-E immune checkpoint pathway in T cells and NK cells for cancer immunotherapy. J. Immunother. Cancer 12, 1\u201314 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"2827_CR23","doi-asserted-by":"publisher","first-page":"101568","DOI":"10.1016\/j.beha.2024.101568","volume":"37","author":"NA Beelen","year":"2024","unstructured":"Beelen, N. A., Valckx, V. T. C., Bos, G. M. J. & Wieten, L. Interfering with KIR and NKG2A immune checkpoint axes to unleash NK cell immunotherapy. Best. Pr. Res Clin. Haematol. 37, 101568 (2024).","journal-title":"Best. Pr. Res Clin. Haematol."},{"key":"2827_CR24","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jcyt.2023.03.006","volume":"25","author":"M Karvouni","year":"2023","unstructured":"Karvouni, M. et al. Challenges in alphaCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide. Cytotherapy 25, 763\u2013772 (2023).","journal-title":"Cytotherapy"},{"key":"2827_CR25","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00262-015-1744-y","volume":"65","author":"G Pietra","year":"2016","unstructured":"Pietra, G. et al. Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias. Cancer Immunol. Immunother. 65, 465\u2013476 (2016).","journal-title":"Cancer Immunol. Immunother."},{"key":"2827_CR26","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1038\/s41591-025-03640-8","volume":"31","author":"Y Nieto","year":"2025","unstructured":"Nieto, Y. et al. Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial. Nat. Med 31, 1987\u20131993 (2025).","journal-title":"Nat. Med"},{"key":"2827_CR27","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin, D. et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1\/2 trial. Nat. Med. 30, 772\u2013784 (2024).","journal-title":"Nat. Med."},{"key":"2827_CR28","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu, E. et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N. Engl. J. Med. 382, 545\u2013553 (2020).","journal-title":"N. Engl. J. Med"},{"key":"2827_CR29","doi-asserted-by":"publisher","first-page":"957","DOI":"10.3389\/fimmu.2019.00957","volume":"10","author":"T Ingegnere","year":"2019","unstructured":"Ingegnere, T. et al. Human CAR NK cells: a new non-viral method allowing high efficient transfection and strong tumor cell killing. Front. Immunol. 10, 957 (2019).","journal-title":"Front. Immunol."},{"key":"2827_CR30","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s13046-025-03453-0","volume":"44","author":"F De Mitri","year":"2025","unstructured":"De Mitri, F. et al. Inhibition of autophagy enhances the antitumor efficacy of T\/CAR T cell against neuroblastoma. J. Exp. Clin. Cancer Res. 44, 185 (2025).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2827_CR31","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu, B., Zhang, B., Li, B., Wu, H. & Jiang, M. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct. Target Ther. 9, 274 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"2827_CR32","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.ccell.2024.09.010","volume":"42","author":"C Galassi","year":"2024","unstructured":"Galassi, C., Chan, T. A., Vitale, I. & Galluzzi, L. The hallmarks of cancer immune evasion. Cancer Cell 42, 1825\u20131863 (2024).","journal-title":"Cancer Cell"},{"key":"2827_CR33","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/s43018-025-00940-3","volume":"6","author":"W Lei","year":"2025","unstructured":"Lei, W. et al. Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory\/relapsed large B cell lymphoma: a phase 1 trial. Nat. Cancer 6, 786\u2013800 (2025).","journal-title":"Nat. Cancer"},{"key":"2827_CR34","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.4049\/jimmunol.1500300","volume":"195","author":"Y Guo","year":"2015","unstructured":"Guo, Y. et al. IL-15 Superagonist-Mediated Immunotoxicity: Role of NK Cells and IFN-gamma. J. Immunol. 195, 2353\u20132364 (2015).","journal-title":"J. Immunol."},{"key":"2827_CR35","doi-asserted-by":"crossref","unstructured":"Christodoulou, I. et al. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities. J. Immunother. Cancer 9 (2021).","DOI":"10.1101\/2021.09.23.461509"},{"key":"2827_CR36","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41416-023-02332-9","volume":"129","author":"T Lorenzini","year":"2023","unstructured":"Lorenzini, T. et al. Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy. Br. J. Cancer 129, 696\u2013705 (2023).","journal-title":"Br. J. Cancer"},{"key":"2827_CR37","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.molimm.2020.04.016","volume":"122","author":"C Lu","year":"2020","unstructured":"Lu, C. et al. A novel chimeric PD1-NKG2D-41BB receptor enhances antitumor activity of NK92 cells against human lung cancer H1299 cells by triggering pyroptosis. Mol. Immunol. 122, 200\u2013206 (2020).","journal-title":"Mol. Immunol."},{"key":"2827_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1073\/pnas.2107507118","volume":"118","author":"J Wang","year":"2021","unstructured":"Wang, J. et al. Multispecific targeting of glioblastoma with tumor microenvironment-responsive multifunctional engineered NK cells. Proc. Natl. Acad. Sci. USA 118, 1\u201312 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2827_CR39","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.trecan.2024.01.003","volume":"10","author":"GJ Kembuan","year":"2024","unstructured":"Kembuan, G. J., Kim, J. Y., Maus, M. V. & Jan, M. Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology. Trends Cancer 10, 312\u2013331 (2024).","journal-title":"Trends Cancer"},{"key":"2827_CR40","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","volume":"8","author":"N Xie","year":"2023","unstructured":"Xie, N. et al. Neoantigens: promising targets for cancer therapy. Signal Transduct. Target Ther. 8, 9 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2827_CR41","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","volume":"626","author":"E Vivier","year":"2024","unstructured":"Vivier, E. et al. Natural killer cell therapies. Nature 626, 727\u2013736 (2024).","journal-title":"Nature"},{"key":"2827_CR42","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","volume":"6","author":"H Zhao","year":"2021","unstructured":"Zhao, H. et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct. Target Ther. 6, 263 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"2827_CR43","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson, V. et al. The immune landscape of cancer. Immunity 48, 812\u2013830 e814 (2018).","journal-title":"Immunity"},{"key":"2827_CR44","doi-asserted-by":"publisher","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","volume":"8","author":"R Romee","year":"2016","unstructured":"Romee, R. et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci. Transl. Med. 8, 357ra123 (2016).","journal-title":"Sci. Transl. Med"},{"key":"2827_CR45","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/ni.3518","volume":"17","author":"C Guillerey","year":"2016","unstructured":"Guillerey, C., Huntington, N. D. & Smyth, M. J. Targeting natural killer cells in cancer immunotherapy. Nat. Immunol. 17, 1025\u20131036 (2016).","journal-title":"Nat. Immunol."},{"key":"2827_CR46","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","volume":"175","author":"P Andre","year":"2018","unstructured":"Andre, P. et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK Cells. Cell 175, 1731\u20131743 e1713 (2018).","journal-title":"Cell"},{"key":"2827_CR47","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s40425-019-0761-3","volume":"7","author":"T van Hall","year":"2019","unstructured":"van Hall, T. et al. Monalizumab: inhibiting the novel immune checkpoint NKG2A. J. Immunother. Cancer 7, 263 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"2827_CR48","doi-asserted-by":"publisher","first-page":"e1238","DOI":"10.1002\/cti2.1238","volume":"10","author":"L Riggan","year":"2021","unstructured":"Riggan, L., Shah, S. & O\u2019Sullivan, T. E. Arrested development: suppression of NK cell function in the tumor microenvironment. Clin. Transl. Immunol. 10, e1238 (2021).","journal-title":"Clin. Transl. Immunol."},{"key":"2827_CR49","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1002\/ijc.34389","volume":"152","author":"N Tumino","year":"2023","unstructured":"Tumino, N. et al. The tumor microenvironment drives NK cell metabolic dysfunction leading to impaired antitumor activity. Int J. Cancer 152, 1698\u20131706 (2023).","journal-title":"Int J. Cancer"},{"key":"2827_CR50","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.cmet.2023.02.013","volume":"35","author":"CB Nava Lauson","year":"2023","unstructured":"Nava Lauson, C. B. et al. Linoleic acid potentiates CD8(+) T cell metabolic fitness and antitumor immunity. Cell Metab. 35, 633\u2013650 e639 (2023).","journal-title":"Cell Metab."},{"key":"2827_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.96219","volume":"3","author":"M Felices","year":"2018","unstructured":"Felices, M. et al. Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect. JCI Insight 3, 1\u201314 (2018).","journal-title":"JCI Insight"},{"key":"2827_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01900-0","volume":"22","author":"P Knopf","year":"2023","unstructured":"Knopf, P. et al. Acidosis-mediated increase in IFN-gamma-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors. Mol. Cancer 22, 207 (2023).","journal-title":"Mol. Cancer"},{"key":"2827_CR53","doi-asserted-by":"publisher","first-page":"e1509819","DOI":"10.1080\/2162402X.2018.1509819","volume":"7","author":"JL Oyer","year":"2018","unstructured":"Oyer, J. L., Gitto, S. B., Altomare, D. A. & Copik, A. J. PD-L1 blockade enhances anti-tumor efficacy of NK cells. Oncoimmunology 7, e1509819 (2018).","journal-title":"Oncoimmunology"},{"key":"2827_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51500-9","volume":"15","author":"I Pallavicini","year":"2024","unstructured":"Pallavicini, I. et al. LSD1 inhibition improves efficacy of adoptive T cell therapy by enhancing CD8(+) T cell responsiveness. Nat. Commun. 15, 7366 (2024).","journal-title":"Nat. Commun."},{"key":"2827_CR55","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1158\/1078-0432.CCR-14-2998","volume":"21","author":"I Caruana","year":"2015","unstructured":"Caruana, I. et al. K562-Derived Whole-Cell Vaccine Enhances Antitumor Responses of CAR-Redirected Virus-Specific Cytotoxic T Lymphocytes In Vivo. Clin. Cancer Res. 21, 2952\u20132962 (2015).","journal-title":"Clin. Cancer Res."},{"key":"2827_CR56","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s00262-022-03340-z","volume":"72","author":"PF Fiore","year":"2023","unstructured":"Fiore, P. F. et al. Different effects of NK cells and NK-derived soluble factors on cell lines derived from primary or metastatic pancreatic cancers. Cancer Immunol. Immunother. 72, 1417\u20131428 (2023).","journal-title":"Cancer Immunol. Immunother."},{"key":"2827_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/cpz1.357","volume":"2","author":"SJ Roper","year":"2022","unstructured":"Roper, S. J. & Coyle, B. Establishing an in vitro 3D spheroid model to study medulloblastoma drug response and tumor dissemination. Curr. Protoc. 2, e357 (2022).","journal-title":"Curr. Protoc."},{"key":"2827_CR58","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jim.2017.04.003","volume":"447","author":"H Zhang","year":"2017","unstructured":"Zhang, H. et al. Novel high-throughput cell-based hybridoma screening methodology using the Celigo Image Cytometer. J. Immunol. Methods 447, 23\u201330 (2017).","journal-title":"J. Immunol. Methods"},{"key":"2827_CR59","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s00401-021-02347-7","volume":"142","author":"F Nazio","year":"2021","unstructured":"Nazio, F. et al. Targeting cancer stem cells in medulloblastoma by inhibiting AMBRA1 dual function in autophagy and STAT3 signalling. Acta Neuropathol. 142, 537\u2013564 (2021).","journal-title":"Acta Neuropathol."},{"key":"2827_CR60","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/978-1-60761-786-0_7","volume":"651","author":"A Di Stasi","year":"2010","unstructured":"Di Stasi, A., De Angelis, B. & Savoldo, B. Gene therapy to improve migration of T cells to the tumor site. Methods Mol. Biol. 651, 103\u2013118 (2010).","journal-title":"Methods Mol. Biol."},{"key":"2827_CR61","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"2827_CR62","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2827_CR63","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha, V. K. et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267\u2013273 (2003).","journal-title":"Nat. Genet."},{"key":"2827_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/bioinformatics\/btac757","volume":"39","author":"Z Fang","year":"2023","unstructured":"Fang, Z., Liu, X. & Peltz, G. GSEApy: a comprehensive package for performing gene set enrichment analysis in Python. Bioinformatics 39, 1\u20133 (2023).","journal-title":"Bioinformatics"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02827-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02827-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02827-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T23:01:23Z","timestamp":1783638083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02827-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2827"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02827-w","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"269"}}